1. At a Glance – This Is Not Just Another EPC Story

Most “engineering companies” sell steel, cement and PowerPoints.

Fabtech seems to be selling something far more valuable — regulatory compliance wrapped in cleanrooms, purified water, and biopharma infrastructure.

That distinction matters.

This is a company with:

• FY26 revenue at ₹411 crore, up from ₹327 crore.
• PAT at ₹38 crore.
• ₹900+ crore order book, over 2.2x annual revenue.
• Presence in 62 countries.
• Export-heavy model with 85.7% international revenues.
• Asset-light structure, yet surprisingly respectable 13.6% ROCE.
• Listed just months ago and already talking acquisitions.

And yet market cap sits near ₹783 crore, barely 1.9x sales.

That mismatch deserves attention.

Usually when markets assign low multiples, one of three things is happening:

1. It is junk disguised as growth.
2. It is lumpy and misunderstood.
3. It is early.

Fabtech appears to be fighting for category 2 or maybe even 3.

Interesting part?

Management is not pitching itself as contractor. In the February concall, they practically rejected that label.

“We are not a conventional contractor.”

That line matters.

Contractors get low multiples.

Platforms get premium multiples.

Management is clearly trying to migrate investor perception from EPC to life-sciences infrastructure platform.

Whether they earn that re-rating is the story.

And there are clues.

Order intake:

• FY23: ₹289 crore
• FY24: ₹404 crore
• FY25: ₹476 crore

Projects delivered:

• 4 → 19 → 51

Proposal conversion:

• 7.8% → 10.2%

That is not random.

That looks like scaling.

Question for readers:

Is this an underfollowed niche compounder…

Or just a glorified project business with fancy vocabulary?

That debate is where the money often gets made.

Dry observation:

Most companies use IPO money to buy office chairs.

Fabtech wants to buy manufacturers in India, UAE, KSA and Egypt.

Slightly different ambition.

2. Introduction – Why This Story Is Strange

Normally SMEs coming to mainboard arrive with:

• stretched balance sheets
• promoter pledges
• aggressive narratives
• suspicious receivables

Fabtech has receivable issues (182 debtor days — not small).

But the rest?

Cleaner than expected.

Promoter holding:
68.94%

No pledges.

Debt/equity:
0.17

Cash jumped:
₹35 crore to ₹208 crore after IPO.

That changes survival math.

Now the more interesting bit.

They operate where countries want pharmaceutical self-sufficiency.

Africa.
Middle East.
GCC.

Not saturated markets.

Emerging demand creation markets.

That is different from fighting for share in a mature market.

And management is riding that theme aggressively.

Saudi vaccine facilities.
North African EU-GMP veterinary plant.
West Africa OSD project.

This is not random order flow.

This is thematic positioning.

Now add this:

Order book moved from ₹762 crore FY25 to ₹900 crore+ now.

That is growth even after execution.

Usually you want to see order books replenish.

They are.

Important nuance:

Q3 softness worried investors.

Management blamed shipment-led revenue recognition.

And Q4 appears to have validated that explanation.

Management walked the talk here.

That matters a lot.

Old concall promise:
Q4 catch-up.

Actual:
March quarter sales ₹159 crore versus ₹63 crore previous quarter.